US Patent 11932851 Exon skipping compositions for treating muscular dystrophy
Patent 11932851 was granted and assigned to Sarepta Therapeutics on March, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 21 Mar, 2024
Golden AI
Edits made to:
Infobox (+84 properties)
Article (+150 characters)
US Patent 11932851 Exon skipping compositions for treating muscular dystrophy
Article
Patent abstract
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Diane Elizabeth Frank0
Richard K. Bestwick0
Date of Patent
March 19, 2024
0Patent Application Number
171307160
Date Filed
December 22, 2020
0Patent Citations
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Patent Primary Examiner
Find more entities like US Patent 11932851 Exon skipping compositions for treating muscular dystrophy
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.